Main content

Hexvix® featured during the 2017 annual EAU congress

Oslo, Norway, March 29, 2017, Photocure ASA (OSE: PHO), is pleased to announce that Blue Light Cystoscopy (BLC™) with Hexvix® was featured during the European Association of Urology (EAU) annual meeting held in London, UK, March 24th - 28th. The EAU is one of the largest international meetings in urology, attended by more than 12,000 urologists from over 110 countries.

Blue Light Cystoscopy (BLCTM) with Hexvix® was included in a presentation onThe future of non-muscle-invasive bladder cancer management” by S. Shariat, Department of Urology Comprehensive Cancer Care Medical Center of Vienna, Austria, in an industry symposium sponsored by Ipsen, Photocure’s strategic partner for the commercialization of Hexvix® in Europe, excluding the Nordic region. 

Blue light cystoscopy with Hexvix® was included in several presentations and also featured in an EAU video demonstrating an innovative outpatient bladder cancer treatment procedure. See the video here (02:45).

For further information, please contact:

Photocure:
Kjetil Hestdal
President and CEO
Photocure ASA
Tel 47 913 19 535
KH@photocure.com

About Hexvix®/Cysview®
Hexvix® is a drug that is taken up selectively by cancer cells in the bladder making them glow bright pink during Blue Light Cystoscopy (BLC).  BLC with Hexvix® improves the detection of tumors and leads to more complete resection, less residual tumors and better management decisions (US)/ reduced risk of recurrence and progression (Nordic)*

Hexvix® is the tradename in Europe, Cysview® in the US and Canada. Hexvix® is marketed and sold by Photocure in the Nordic countries and in the US with the trade name Cysview®. Photocure has a strategic partnership with Ipsen for the commercialization of Hexvix® in Europe, excluding the Nordic region.  Please refer to https://www.photocure.com/Partnering-with-Photocure/Our-partners for further information on our commercial partners. 

About Photocure
Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on its unique proprietary Photocure Technology® platform, Photocure develops and commercializes highly selective and effective solutions in disease areas with high-unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, and skin conditions. Photocure’s aim is to provide solutions which can improve health outcomes for patients worldwide. The company is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at www.photocure.com. 

About Bladder Cancer
There are 167 000 new cases of bladder cancer in Europe and more than 59 000 deaths from the disease annually. 79% of all bladder cancer cases occur in men1. It has a high recurrence rate with an average of 61% in year one and 78% over five years, making the lifetime costs of managing bladder cancer one of the highest amongst all. Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence2. A recent paper on the economic burden of bladder cancer across the European Union estimates that bladder cancer cost the EU 4.9 Billion Euro in 2012.3

Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies because of the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike. 

Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall.4   NMIBC is still in the inner layer of cells. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. MIBC is when the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.5

1. Globocan. Incidence/mortality by population.  Available at: http://globocan.iarc.fr/Pages/bar_pop_sel.aspx 
2. Leal et al, Eur Urol 2016; 69: 438-447
3. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS). Eur Urol. 2016 Guidelines Edition:1-40.
3. Sievert KD et al. World J Urol 2009;27:295–300
4. Bladder Cancer. American Cancer Society. http://www.cancer.org/acs/groups/cid/documents/webcontent/003085-pdf.pdf. Accessed April 2016.
5. Bladder Cancer. American Cancer Society. http://www.cancer.org/acs/groups/cid/documents/webcontent/003085-pdf.pdf. Accessed April 2016.

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA

Right column